Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.

Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E.

Int J Cancer. 2019 Oct 1;145(7):1902-1912. doi: 10.1002/ijc.32266. Epub 2019 Apr 4.

PMID:
30859564
2.

Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.

Pouzoulet F, Alentorn A, Royer-Perron L, Assayag F, Mokhtari K, Labiod D, Le Garff-Tavernier M, Daniau M, Menet E, Peyre M, Schnitzler A, Guegan J, Davi F, Hoang-Xuan K, Soussain C.

Blood Cells Mol Dis. 2019 Mar;75:1-10. doi: 10.1016/j.bcmd.2018.11.005. Epub 2018 Nov 16.

PMID:
30502564
3.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.

Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.

4.

The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Sep;246(1):103-114. doi: 10.1002/path.5104. Epub 2018 Aug 7.

PMID:
29876931
5.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

6.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

7.

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Tury S, Becette V, Assayag F, Vacher S, Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F, Callens C.

Oncotarget. 2016 Dec 20;7(51):85124-85141. doi: 10.18632/oncotarget.13200.

8.

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts.

Assayag F, Nicolas A, Vacher S, Dehainault C, Bieche I, Meseure D, Aerts I, Cassoux N, Houdayer C, Doz F, Decaudin D.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4916-4926. doi: 10.1167/iovs.15-18725.

PMID:
27654418
9.

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D.

PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016.

10.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

11.

Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing.

Cassoux N, Thuleau A, Assayag F, Aerts I, Decaudin D.

Ocul Oncol Pathol. 2015 Apr;1(3):200-6. doi: 10.1159/000370156. Epub 2015 Apr 9. Review.

12.

Supersonic Shear Wave Elastography of Response to Anti-cancer Therapy in a Xenograft Tumor Model.

Chamming's F, Le-Frère-Belda MA, Latorre-Ossa H, Fitoussi V, Redheuil A, Assayag F, Pidial L, Gennisson JL, Tanter M, Cuénod CA, Fournier LS.

Ultrasound Med Biol. 2016 Apr;42(4):924-30. doi: 10.1016/j.ultrasmedbio.2015.12.001. Epub 2015 Dec 30.

PMID:
26746382
13.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D.

Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12.

PMID:
25503779
14.

Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.

Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E.

Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19.

15.

Shear wave elastography of tumour growth in a human breast cancer model with pathological correlation.

Chamming's F, Latorre-Ossa H, Le Frère-Belda MA, Fitoussi V, Quibel T, Assayag F, Marangoni E, Autret G, Balvay D, Pidial L, Gennisson JL, Tanter M, Cuenod CA, Clément O, Fournier LS.

Eur Radiol. 2013 Aug;23(8):2079-86. doi: 10.1007/s00330-013-2828-8. Epub 2013 Apr 4.

PMID:
23553589
16.

Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.

Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E.

Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25.

17.

Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.

Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L, Mariani P, Lantz O, Stern MH.

Clin Cancer Res. 2012 Jul 15;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309. Epub 2012 May 29.

18.

Molecular profiling of patient-derived breast cancer xenografts.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E.

Breast Cancer Res. 2012 Jan 16;14(1):R11.

19.

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.

Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16.

PMID:
22002565
20.

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.

de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E.

Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28.

21.

A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.

Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.

Anticancer Drugs. 2010 Nov;21(10):927-31. doi: 10.1097/CAD.0b013e32833db887.

PMID:
20827173
22.

Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D.

Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29.

PMID:
19823076
23.

Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab.

Assayag F, Brousse N, Couturier J, Macintyre E, Mathiot C, Dewulf S, Froget B, Vincent-Salomon A, Decaudin D.

Am J Hematol. 2009 Jun;84(6):387-8. doi: 10.1002/ajh.21415. No abstract available.

24.

Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B.

Lejmi E, Leconte L, Pédron-Mazoyer S, Ropert S, Raoul W, Lavalette S, Bouras I, Feron JG, Maitre-Boube M, Assayag F, Feumi C, Alemany M, Jie TX, Merkulova T, Poupon MF, Ruchoux MM, Tobelem G, Sennlaub F, Plouët J.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12491-6. doi: 10.1073/pnas.0804008105. Epub 2008 Aug 21.

25.

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF.

Clin Cancer Res. 2007 Jul 1;13(13):3989-98.

26.
27.

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF.

Cancer Res. 2007 Jan 1;67(1):398-407.

28.

Supplemental Content

Loading ...
Support Center